Shidong Jia
YOU?
Author Swipe
View article: Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
Gene alterations associated with shorter PFS.
View article: Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and …
View article: Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
DNA sequencing data summary.
View article: Psychosocial Profiles of Family Caregivers for Colorectal Cancer Patients with Permanent Ostomies: A Latent Class Analysis of Resilience, Depression, and Self-Efficacy
Psychosocial Profiles of Family Caregivers for Colorectal Cancer Patients with Permanent Ostomies: A Latent Class Analysis of Resilience, Depression, and Self-Efficacy Open
Purpose To identify latent psychosocial profiles among colorectal cancer caregivers based on resilience, depression, and caregiving efficacy, and to examine the sociodemographic predictors and outcome differences associated with each subgr…
View article: Augmented prediction of multi-species protein–RNA interactions using evolutionary conservation of RNA-binding proteins
Augmented prediction of multi-species protein–RNA interactions using evolutionary conservation of RNA-binding proteins Open
RNA-binding proteins (RBPs) play critical roles in gene expression regulation. Recent studies have begun to detail the RNA recognition mechanisms of diverse RBPs. However, given the array of RBPs studied so far, it is implausible to experi…
View article: BIOM-05 CHARACTERIZATION OF TUMOR-DERIVED DNA MUTATIONS, COPY NUMBER CHANGES, AND METHYLATED FRAGMENTS WITHIN CEREBROSPINAL FLUID AND PLASMA FROM PATIENTS UNDERGOING SURGERY FOR LUNG CANCER BRAIN METASTASIS
BIOM-05 CHARACTERIZATION OF TUMOR-DERIVED DNA MUTATIONS, COPY NUMBER CHANGES, AND METHYLATED FRAGMENTS WITHIN CEREBROSPINAL FLUID AND PLASMA FROM PATIENTS UNDERGOING SURGERY FOR LUNG CANCER BRAIN METASTASIS Open
Surgical management of brain metastasis (BrM) improves outcomes in selected patients, yet predicting CNS progression following surgery remains challenging. To identify circulating tumor-(ct)DNA markers associated with disease progression, …
View article: The evolution of FLASH radiotherapy: a bibliometric analysis
The evolution of FLASH radiotherapy: a bibliometric analysis Open
Introduction FLASH radiotherapy (FLASH-RT) represents a groundbreaking technique, characterized by its ultra-high dose rate and its remarkable ability to spare normal tissues from damage. Numerous studies on FLASH-RT have been conducted wo…
View article: Editorial Expression of Concern: Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Editorial Expression of Concern: Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis Open
View article: Supplementary Table S1 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Supplementary Table S1 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Table S1. Baseline Demographic and Disease Characteristics
View article: Data from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Data from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Purpose:Detecting residual disease is a critical clinical requirement in the perisurgical management of patients with resectable hepatocellular carcinoma (HCC). Previous studies focused on specific genomic regions exhibiting limited sensit…
View article: Supplementary Figure S3 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Supplementary Figure S3 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Kaplan-Meier analysis of Recurrence-Free Survival (RFS) and Overall Survival (OS) based on ctDNA positivity using a heightened threshold of 0.1% tumor fraction in post-surgical plasma samples in BCLC stage 0-A patients using MRD assay. A. …
View article: Supplementary Table S2 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Supplementary Table S2 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Table S2a. Mutational measurements of each tissue/plasma sample in our study. Table S2b. Somatic SNVs and InDels of basal tissue samples detected by whole exome sequencing. Table S2c. SNVs and InDels detected by personalized MRD and fixed …
View article: Supplementary Figure S2 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Supplementary Figure S2 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Kaplan-Meier analysis of Recurrence-Free Survival (RFS) and Overall Survival (OS) based on ctDNA detection in presurgical plasma samples using MRD assay. A. Association between pre-surgical MRD status and RFS. B. Association between pre-su…
View article: Supplementary Figure S1 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Supplementary Figure S1 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Kaplan-Meier analysis of Recurrence-Free Survival (RFS) and Overall Survival (OS) based on gene variations in surgical tissue samples. A. Association between TP53 status and RFS. B. Association between TP53 status and OS. C. Association be…
View article: Supplementary Figure S4 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Supplementary Figure S4 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Kaplan-Meier analysis of RFS and OS based on tumor fraction risk in pre-surgical plasma samples: A, B. TF<0.1%-low risk, TF ≥ 0.1%-high risk; C, D. TF<1%-low risk, TF ≥ 1%-high risk. P-values are based on log-rank tests. A. Association bet…
View article: Supplementary Figure S5 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
Supplementary Figure S5 from Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma Open
Kaplan-Meier analysis of Overall Survival (OS) based on tumor fractions detection in post-surgical plasma samples in BCLC stage 0-A patients using MRD assay. Tumor fraction cutoff is 0.1%.
View article: Supplemental Table 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA Open
Supplemental Table 1. List of 152 genes on PredicineCARE panel.
View article: Supplemental Table 3 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 3 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA Open
Supplementary Table 3. Representativeness of Study Participants.
View article: Supplemental Table 2 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 2 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA Open
Supplemental Table 2. Tissue vs. CSF NGS in patients 24, 78, and 79.
View article: Supplementary Materials 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Materials 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA Open
Supplementary Materials, including Figures/Figure legends S1-2 and note on Predicine CARE/CNB validation.
View article: Data from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Data from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA Open
Purpose:Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliom…
View article: Effectiveness of digital modified behavioral activation treatment program for rural older adults with depressive symptoms in Western Hunan: study protocol for a multi-center randomized controlled trial
Effectiveness of digital modified behavioral activation treatment program for rural older adults with depressive symptoms in Western Hunan: study protocol for a multi-center randomized controlled trial Open
Chinese Clinical Trial Registry ChiCTR2400091193. Registered on 23 October 2024.
View article: Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA Open
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with glio…
View article: Bone matching versus tumor matching in image-guided carbon ion radiotherapy for locally advanced non-small cell lung cancer
Bone matching versus tumor matching in image-guided carbon ion radiotherapy for locally advanced non-small cell lung cancer Open
TM exhibited superior target dose coverage compared to BM, particularly in cases of larger tumor displacement. TM also demonstrated better tolerance to variations in tumor morphology.
View article: Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
Patient demographics.
View article: Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
DNA sequencing data summary.
View article: Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
PredicineATLAS gene panel.
View article: Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
Supplementary Methods
View article: Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
Gene alterations associated with shorter PFS.
View article: Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer Open
Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and …